Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
International Journal of Cancer|November 10, 2018
Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trialDarrel A Cook, Mel Krajden, Adam R Brentnall, et al.
The Journal of Infectious Diseases|February 22, 2024
Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older AdultsChristine A Shaw, Brandon Essink, Charles Harper, et al.
Respiratory Investigation|September 10, 2024
Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged ≥60 years: A phase 1, randomized, observer-blind, placebo-controlled trialDavid Fitz-Patrick, Hanako Mihara, Anthony Mills, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 24, 2025
Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 YearsJaya Goswami, Jose F Cardona, Jorge Caso, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 4, 2025
Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18-59 YearsErick F Mayer, Ann R Falsey, Rebecca Clark, et al.
Vaccine|July 19, 2025
Understanding the decline in HPV vaccination in Colombia: A population-based analysis of girls and parents in early rollout cohortsKaren Cárdenas-Garzon, María Cecilia Agudelo, Olga Lucia Tovar-Aguirre, et al.
The Lancet. Infectious Diseases|November 28, 2024
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trialJaya Goswami, Jose F Cardona, Denise C Hsu, et al.
The New England Journal of Medicine|December 13, 2023
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older AdultsEleanor Wilson, Jaya Goswami, Abdullah H Baqui, et al.
The New England Journal of Medicine|October 19, 2022
Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of AgeEvan J Anderson, C Buddy Creech, Vladimir Berthaud, et al.
Science Translational Medicine|July 30, 2025
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trialK Rachael Parks, Zoe Moodie, Mary A Allen, et al.
Pageof 4